• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有中央气道阻塞与无中央气道阻塞的晚期肺癌的结局。

Outcome of advanced lung cancer with central airway obstruction without central airway obstruction.

作者信息

Verma Akash, Goh Soon Keng, Tai Dessmon Y H, Kor Ai Ching, Soo Chun Ian, Seow Debra G F, Sein Zin Nge Nge, Samol Jens, Chopra Akhil, Abisheganaden John

机构信息

Dept of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore.

出版信息

ERJ Open Res. 2018 Apr 9;4(2). doi: 10.1183/23120541.00173-2017. eCollection 2018 Apr.

DOI:10.1183/23120541.00173-2017
PMID:29637076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5890022/
Abstract

Patients with central airway obstruction (CAO) from advanced lung cancer present with significant morbidity and are assumed to have lower survival. Hence, they are offered only palliative support. We asked if patients who have advanced lung cancer with CAO (recanalised and treated) will behave similarly to those with advanced lung cancer without CAO. This study was a retrospective review of the medical records of the patients managed for advanced lung cancer during 2010 and 2015 at our institution. 85 patients were studied. Median survival and 1-, 2- and 5-year survival were 5.8 months, 30.3%, 11.7% and 2.3% 9.3 months, 35.7%, 9.6% and 4.7%, respectively, in the CAO and no CAO groups (p=0.30). More patients presented with respiratory failure (15 (35%) none; p=0.0001) and required assisted mechanical ventilation (10 (23.3%) none; p=0.001) in the CAO group compared with the no CAO group. Fewer patients received chemotherapy in the CAO group (11 (25.5%)) compared with the no CAO group (23 (54.7%); p=0.008). There was no difference in survival among patients with advanced lung cancer whether they presented with CAO or without CAO. Survival was similar to those without CAO in patients with recanalised CAO despite greater morbidity and lesser use of chemotherapy, strongly advocating bronchoscopic recanalisation of CAO. These findings dispel the nihilism associated with such cases.

摘要

晚期肺癌导致中央气道阻塞(CAO)的患者具有较高的发病率,且生存期较短。因此,他们仅接受姑息治疗。我们想了解晚期肺癌合并CAO(已再通并接受治疗)的患者与无CAO的晚期肺癌患者的表现是否相似。本研究回顾性分析了2010年至2015年在我院接受治疗的晚期肺癌患者的病历。共研究了85例患者。CAO组和无CAO组的中位生存期及1年、2年和5年生存率分别为5.8个月、30.3%、11.7%和2.3%,以及9.3个月、35.7%、9.6%和4.7%(p=0.30)。与无CAO组相比,CAO组更多患者出现呼吸衰竭(15例(35%)对0例;p=0.0001)且需要机械通气辅助(10例(23.3%)对0例;p=0.001)。与无CAO组(23例(54.7%))相比,CAO组接受化疗的患者更少(11例(25.5%);p=0.008)。晚期肺癌患者无论是否合并CAO,其生存率无差异。尽管CAO患者发病率更高且化疗使用率更低,但再通CAO的患者生存率与无CAO患者相似,这强烈支持对CAO进行支气管镜再通治疗。这些发现消除了与此类病例相关的虚无主义观念。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252c/5890022/10de382bf894/00173-2017.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252c/5890022/10de382bf894/00173-2017.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252c/5890022/10de382bf894/00173-2017.01.jpg

相似文献

1
Outcome of advanced lung cancer with central airway obstruction without central airway obstruction.有中央气道阻塞与无中央气道阻塞的晚期肺癌的结局。
ERJ Open Res. 2018 Apr 9;4(2). doi: 10.1183/23120541.00173-2017. eCollection 2018 Apr.
2
Bronchoscopic intervention obviates the need for continued mechanical ventilation in patients with airway obstruction and respiratory failure from inoperable non-small-cell lung cancer.支气管镜介入治疗可避免因无法手术的非小细胞肺癌导致气道阻塞和呼吸衰竭的患者持续机械通气。
Respiration. 2012;84(1):55-61. doi: 10.1159/000339316. Epub 2012 Jun 29.
3
Stenting in Non-Small Cell Lung Cancer: How Does It Affect the Outcomes?非小细胞肺癌的支架置入术:它如何影响治疗结果?
Asian Pac J Cancer Prev. 2020 Jan 1;21(1):175-178. doi: 10.31557/APJCP.2020.21.1.175.
4
Prevalence and outcome of central airway obstruction in patients with lung cancer.肺癌患者中央气道阻塞的患病率和结局。
BMJ Open Respir Res. 2019 Sep 24;6(1):e000429. doi: 10.1136/bmjresp-2019-000429. eCollection 2019.
5
Reporting of central airway obstruction on radiology reports and impact on bronchoscopic airway interventions and patient outcomes.放射学报告中关于中央气道阻塞的报告及其对支气管镜气道干预和患者预后的影响。
Ther Adv Respir Dis. 2016 Apr;10(2):105-12. doi: 10.1177/1753465815620111. Epub 2015 Dec 7.
6
Review of the clinical outcomes of therapeutic bronchoscopy for central airway obstruction.治疗性支气管镜检查治疗中央气道阻塞的临床结果综述。
Mediastinum. 2023 Feb 1;7:17. doi: 10.21037/med-22-39. eCollection 2023.
7
Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.伴有和不伴有中央气道阻塞的晚期非小细胞肺癌的治疗结果
Chest. 2006 Dec;130(6):1803-7. doi: 10.1378/chest.130.6.1803.
8
Outcome differences between recanalized malignant central airway obstruction from endoluminal disease versus extrinsic compression.腔内疾病与外在压迫所致再通的恶性中央气道阻塞的结局差异。
Lasers Med Sci. 2019 Jul;34(5):955-962. doi: 10.1007/s10103-018-2684-5. Epub 2018 Nov 12.
9
Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience.中央气道阻塞患者的介入肺脏病学:八年机构经验
Medicine (Baltimore). 2017 Jan;96(2):e5612. doi: 10.1097/MD.0000000000005612.
10
Clinical and radiographic predictors of successful therapeutic bronchoscopy for the relief of malignant central airway obstruction.临床和影像学预测因素对恶性中央气道阻塞缓解的治疗性支气管镜检查的影响。
BMC Pulm Med. 2019 Nov 21;19(1):219. doi: 10.1186/s12890-019-0987-3.

引用本文的文献

1
Interventional bronchoscopy in lung cancer treatment.肺癌治疗中的介入性支气管镜检查
Breathe (Sheff). 2024 Aug 27;20(2):230201. doi: 10.1183/20734735.0201-2023. eCollection 2024 Jun.
2
Overview of malignant central airway obstruction.恶性中央气道梗阻概述。
Mediastinum. 2023 Jul 11;7:32. doi: 10.21037/med-22-44. eCollection 2023.
3
Diagnosis of lung cancer by flexible fiberoptic bronchoscopy: a descriptive study.经纤维支气管镜诊断肺癌:一项描述性研究。

本文引用的文献

1
Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.非小细胞肺癌分期方法:肺癌的诊断与管理,第 3 版:美国胸科学会循证临床实践指南。
Chest. 2013 May;143(5 Suppl):e211S-e250S. doi: 10.1378/chest.12-2355.
2
Neoplastic severe central airways obstruction, interventional bronchoscopy: a decision-making analysis.肿瘤性严重中央气道阻塞,介入性支气管镜检查:决策分析。
J Thorac Cardiovasc Surg. 2013 Apr;145(4):926-932. doi: 10.1016/j.jtcvs.2012.08.066. Epub 2012 Sep 27.
3
Survival of lung adenocarcinoma patients with malignant pleural effusion.
Rom J Morphol Embryol. 2022 Apr-Jun;63(2):369-381. doi: 10.47162/RJME.63.2.08.
4
Feasibility and safety of a novel electrosurgery device as part of multi-modal bronchoscopic therapy for malignant central airway lesions.一种新型电外科设备作为恶性中央气道病变多模式支气管镜治疗一部分的可行性和安全性。
J Thorac Dis. 2021 May;13(5):3151-3159. doi: 10.21037/jtd-20-3001.
5
Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study.在呼吸衰竭的恶性中央气道阻塞患者中,中度镇静下经支气管微波消融治疗的疗效和安全性:单中心回顾性研究。
J Cancer Res Clin Oncol. 2021 Sep;147(9):2751-2757. doi: 10.1007/s00432-021-03560-3. Epub 2021 Feb 24.
6
Prevalence and outcome of central airway obstruction in patients with lung cancer.肺癌患者中央气道阻塞的患病率和结局。
BMJ Open Respir Res. 2019 Sep 24;6(1):e000429. doi: 10.1136/bmjresp-2019-000429. eCollection 2019.
肺腺癌合并恶性胸腔积液患者的生存情况。
Eur Respir J. 2013 Jun;41(6):1409-18. doi: 10.1183/09031936.00069812. Epub 2012 Sep 27.
4
Bronchoscopic intervention obviates the need for continued mechanical ventilation in patients with airway obstruction and respiratory failure from inoperable non-small-cell lung cancer.支气管镜介入治疗可避免因无法手术的非小细胞肺癌导致气道阻塞和呼吸衰竭的患者持续机械通气。
Respiration. 2012;84(1):55-61. doi: 10.1159/000339316. Epub 2012 Jun 29.
5
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.一项随机、安慰剂对照的厄洛替尼维持治疗晚期非小细胞肺癌的前瞻性分子标志物分析:EGFR 和 KRAS。
J Clin Oncol. 2011 Nov 1;29(31):4113-20. doi: 10.1200/JCO.2010.31.8162. Epub 2011 Oct 3.
6
Outcomes of airway stenting for advanced lung cancer with central airway obstruction.晚期肺癌伴中央气道阻塞的气道支架置入术的疗效
Interact Cardiovasc Thorac Surg. 2010 Oct;11(4):425-8. doi: 10.1510/icvts.2010.238196. Epub 2010 Jul 23.
7
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.吉非替尼和多西他赛治疗既往治疗的非小细胞肺癌的分子预后因素:来自随机 III 期 INTEREST 试验的数据。
J Clin Oncol. 2010 Feb 10;28(5):744-52. doi: 10.1200/JCO.2009.24.3030. Epub 2009 Dec 28.
8
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.在加拿大国家癌症研究所临床试验组BR.21研究中,KRAS和EGFR作为厄洛替尼反应生物标志物的作用
J Clin Oncol. 2008 Sep 10;26(26):4268-75. doi: 10.1200/JCO.2007.14.8924. Epub 2008 Jul 14.
9
Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.伴有和不伴有中央气道阻塞的晚期非小细胞肺癌的治疗结果
Chest. 2006 Dec;130(6):1803-7. doi: 10.1378/chest.130.6.1803.
10
Therapeutic bronchoscopy interventions before surgical resection of lung cancer.肺癌手术切除前的治疗性支气管镜介入治疗。
Ann Thorac Surg. 2006 May;81(5):1839-43. doi: 10.1016/j.athoracsur.2005.11.054.